A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

被引：57
|
作者：
Konopleva, Marina [1 ]
Pollyea, Daniel A. [2 ]
Potluri, Jalaja [3 ]
Chyla, Brenda J. [3 ]
Busman, Todd [3 ]
McKeegan, Evelyn [3 ]
Salem, Ahmed [3 ]
Zhu, Ming [3 ]
Ricker, Justin L. [3 ]
Blum, William [4 ]
DiNardo, Courtney D. [1 ]
Dunbar, Martin [3 ]
Kirby, Rachel [3 ]
Falotico, Nancy [3 ]
Leverson, Joel D. [3 ]
Humerickhouse, Rod A. [3 ]
Mabry, Mack [3 ]
Stone, Richard M. [5 ]
Kantarjian, Hagop M. [1 ]
Letai, Anthony G. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.118.118
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    Davids, Matthew Steven
    Seymour, John Francis
    Gerecitano, John F.
    Kahl, Brad S.
    Pagel, John M.
    Wierda, William G.
    Anderson, Mary Ann
    Darden, David E.
    Nolan, Cathy E.
    Gressick, Lori A.
    Yang, Jianning
    Chyla, Brenda J.
    Busman, Todd A.
    Graham, Alison M.
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1
    Chen, Jun
    Jin, Sha
    Tapang, Paul
    Tahir, Stephen K.
    Smith, Morey
    Xue, John
    Zhang, Haichao
    Gao, Wenqing
    Tong, Yunsong
    Clark, Richard
    Ricker, Justin L.
    Penning, Thomas D.
    Albert, Daniel H.
    Phillips, Darren C.
    Souers, Andrew J.
    Leverson, Joel D.
    BLOOD, 2014, 124 (21)
  • [33] Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Ross, Jeremy
    Amiot, Martine
    Chyla, Brenda
    Roberts-Rapp, Lisa
    Goswami, Rasna
    Yan, Sun
    Huang, Xin
    Bhathena, Anahita
    Enschede, Sari Heitner
    Maciag, Paulo
    Humerickhouse, Rod A.
    McKeegan, Evelyn
    BLOOD, 2015, 126 (23)
  • [34] THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IS ACTIVE AND WELL-TOLERATED IN ULTRA HIGH-RISK RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Roberts, A.
    Davids, M.
    Pagel, J.
    Kahl, B.
    Wierda, W.
    Miller, T.
    Gerecitano, J.
    Kipps, T.
    Anderson, M.
    Huang, D.
    Darden, D.
    Gressick, L.
    Nolan, C.
    Yang, J.
    Busman, T.
    Graham, A.
    Cerri, E.
    Enschede, S.
    Humerickhouse, R.
    Seymour, J.
    HAEMATOLOGICA, 2013, 98 : 473 - 473
  • [35] REDUCTION OF TUMOR LYSIS SYNDROME (TLS) RISK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH ABT-199 (GDC-0199): RESULTS OF MODIFICATIONS TO DOSING SCHEDULE AND TLS PROPHYLAXIS
    Seymour, J.
    Roberts, A.
    Stilgenbauer, S.
    Gressick, L. A.
    Rudersdorf, N. K.
    Busman, T.
    Munasinghe, W.
    Wong, S.
    Desai, M.
    Best, A. E.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    HAEMATOLOGICA, 2014, 99 : 321 - 321
  • [36] Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Darden, David
    Morris, Lura
    Ross, Jeremy
    Salem, Ahmed H.
    Munasinghe, Wijith
    Zhu, Ming
    Leverson, Joel
    Maciag, Paulo
    Enschede, Sari Heitner
    Verdugo, Maria
    Humerickhouse, Rod A.
    Harrison, Simon
    BLOOD, 2015, 126 (23)
  • [37] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles A.
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Cartron, Guillaume
    Li, Yan
    Hilger, James
    Mobasher, Mehrdad
    Stilgenbauer, Stephan
    BLOOD, 2015, 126 (23)
  • [38] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Brunvand, Mark
    Choi, Michael Y.
    Dyer, Martin J. S.
    Gribben, John
    Hillmen, Peter
    Jones, Jeffrey
    Li, Yan
    Mobasher, Mehrdad
    Vosganian, Gregory
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
  • [39] Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)
    Pan, Rongqing
    Kojima, Kensuke
    Zheng, Zhuanzhen
    Ruvolo, Vivian R.
    Nichols, Gwen
    Leverson, Joel D.
    Dangl, Markus
    Konopleva, Marina
    Andreeff, Michael
    BLOOD, 2014, 124 (21)
  • [40] ABT-199 (GDC-0199) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: HIGH RESPONSE RATES AMONG PATIENTS WITH HIGH RISK DISEASE FEATURES INCLUDING UNMUTATED IGHV
    Seymour, J. F.
    Davids, M. S.
    Pagel, J. M.
    Kahl, B. S.
    Wierda, W. G.
    Puvvada, S.
    Gerecitano, J. F.
    Kipps, T. J.
    Anderson, M. A.
    Huang, D. C.
    Rudersdorf, N. K.
    Gressick, L. A.
    Montalvo, N. P.
    Yang, J.
    Zhu, M.
    Dunbar, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Roberts, A. W.
    HAEMATOLOGICA, 2014, 99 : 249 - 249
12345